ID
12249
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 BO17072
Keywords
Versions (2)
- 10/1/15 10/1/15 -
- 10/28/15 10/28/15 -
Uploaded on
October 28, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Follow-Up Treatments NCT00090051 BO17072
Follow-Up Subsequent treatments for Chronic Lymphocytic Leukemia NCT00090051 BO17072
Description
Subsequent treatments radiotherapy
Description
site of radiotherapy
Data type
text
Alias
- UMLS CUI [1]
- C1997599
Description
Total dose
Data type
float
Measurement units
- Gy
Alias
- UMLS CUI [1]
- C2986497
Description
Start date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C0808070
Description
End date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C0806020
Description
Ongoing
Data type
boolean
Alias
- UMLS CUI [1]
- C0549178
Description
Surgery
Description
Other treatment
Description
Name of treatment
Data type
text
Alias
- UMLS CUI-1
- C0087111
Description
Start date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI-1
- C0808070
Description
End date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI-1
- C0806020
Description
Ongoing
Data type
boolean
Alias
- UMLS CUI [1]
- C0549178